Antibiotics resistance, the situation in which antibiotics lose their ability to kill or stop growth of a specific bacterium, may occur naturally as a result of mutations in a bacteria's genes (acquired resistance). However, excessive and inapproriate use of antibiotics may accelerate the emergence and spread of antibiotic-resistant bacteria. In Belgium, several national programs have been launched since 2000 in order to increase the awareness of incorrect antibiotics use and problems of bacterial resistance. Since then, outpatient antibiotic use (based on the number of packages) decreased by 36%. Despite this reduction, outpatient use of antibiotics is still high in Belgium compared to other European countries. And, the use has not been declined since 2006 -2007 . Meanwhile, between 2007 and 2013 , the use of antibiotics in hospitals increased by 5.6%.
Set against this background, our aim was to determine whether antibiotics are over-prescribed in Belgium, and if so, what the costs and health consequences of this are. It was the aim to evaluate the potential savings that could be realized in case prescription behavior in Belgium would be similar
Quantification approach:
The total antibiotics consumption (number of pills sold) was determined using IMS Health Belgian Retail Data for the year 2013, available to IMS Health in both countries (Belgium/the Netherlands) via the IMS MIDAS platform. The corresponding total spending was determined taking into account public prices. The difference between current and estimated spending represented potential cost savings through more conscious prescribing and use of antibiotics.
Number
The Netherlands was chosen for comparison because the climate in both countries is the same, and as such the number of viral and bacterial infections is comparable.
Based on the IMS Health Longitudinal Patient Database (LPD) collected from 360 GPs covering about 300,000 patients, we checked the diagnosis, in ICD-10 coding, for which antibiotics were prescribed.
Methods Introduction
Objectives realized in case prescription behavior in Belgium would be similar to the Netherlands, a country known for its strict antibiotic use.
checked the diagnosis, in ICD-10 coding, for which antibiotics were prescribed.
Results and discussion
In 2013, individual consumption of antibiotics was 5.93 pills per person in the Netherlands and approximately two times higher in Belgium (12.66 pills/person). With a 30% smaller population than the Netherlands, spending in Belgium is 3 times higher. figure 1 . The lowest antibiotics consumption was observed in the Netherlands. In contrast, Belgium antibiotics use, at more than double that of the Netherlands, fell into the high usage category -a result that agrees with our own findings. The status of antibiotics resistance in both Belgium and the Netherlands was also evaluated using the most recent data on the prevalence of acquired bacterial resistance in Europe available from the "2013 Report Priority Medicines for Europe and the World". Rates of antibiotics resistant pseudomonas aeruginosa and staphylococcus aureas are higher in Belgium (10-25%) compared to the Netherlands (1-5%), while the prevalence of resistant E.Coli and Klebsiella pneumonia were comparable. Additional data show that the incidence of hospital-acquired bacterial infections within internal care units in Belgium was 1.4 per 1,000 patient days for primary bloodstream infections, and 17.9 per 1000 intubation days for ventilationassociated pneumonia (NSIH, 2012).
The Great influenza Survey (GIS) was implemented in Several European countries to assess influenza like illness (ILI) incidence level in the community. GIS is an internetbased monitoring system that collects data from individuals voluntarily participating in an internet survey. To analyze general practitioners' prescription trends for antibiotics, we used data available from the IMS Health LPD. The table below shows the indications for which antibiotics were mainly used by GPs. Almost 50% of antibiotic use was used in indications where antibiotics are most often not needed because the condition is of a viral nature. 
Conclusions
By comparing Belgium's prescription patterns to the Netherlands, we estimated important potential savings due to antibiotics mis-use/over-use (€71 Mn). The additional health and cost implications of antibiotics resistance were not taken into account. These savings could then be reinvested in covering innovative drugs. Finally, looking at infection-related death rates, there were 22.9 deaths per 100,000 inhabitants in Belgium due to infectious and parasitic diseases (ICD10 A00-B99), compared to an average of 13.9/100,000 in the European Union, and a rate of 12.7/100,000 in the Netherlands (Eurostat data for 2010, Causes of Deaths by Region).
ESAC-Net countries
The evidence reported above (higher antibiotics consumption in Belgium compared to the Netherlands; a high number of infection-related hospitalizations in Belgium; comparable ambulatory infections in Belgium & the Netherlands(ILI), and higher infection-related death rates in Belgium compared to the Netherlands) suggest that antibiotics are likely misused and over prescribed in Belgium.
Based on the current antibiotics consumption in the Netherlands, potentially €71Mn (€71,478,576) in costs could be avoided annually in Belgium (applying the usage (pills/person) of the Netherlands and current cost/pill in Belgium) if antibiotics were to be prescribed more consciously.
